LambdaVision, a biotech innovator leveraging microgravity to manufacture its investigational protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, has closed a $7M seed funding round co-led by Seven Seven Six and Aurelia Foundry Fund, with additional support from Seraphim Space, providing runway into 2027. Millions of people worldwide lose their sight each year to retinal degenerative diseases like retinitis pigmentosa (RP) and age-related macular degeneration (AMD), with few effective treatment options. The funding will advance preclinical development and scale up space-enabled manufacturing of its artificial retina.